TNF Coverting Enzyme Substrate

Product Description

TNF Coverting Enzyme Substrate
Catalog number: B2012971
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 1 mg
Molecular Weight or Concentration: 536.6 g/mol
Supplied as: Lyophilized Powder
Applications: molecular tool for various biochemical applications
Storage: -20°C
Keywords: MCA-Pro-Leu-Ala-Gln-Ala-Val-DNP-Dap-Arg-Ser-Ser-Ser-Arg-NH2
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Tang G, Li S, Zhang C, Chen H, Wang N, Feng Y. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management Acta Pharm Sin B. 2021 Sep;11(9):2749-2767.
2: Soós B, Fagyas M, Horváth Á, Végh E, Pusztai A, Czókolyová M, Csongrádi A, Hamar A, Pethő Z, Bodnár N, Kerekes G, Hodosi K, Szekanecz É, Szamosi S, Szántó S, Szűcs G, Papp Z, Szekanecz Z. Angiotensin Converting Enzyme Activity in Anti-TNF-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients Front Med (Lausanne). 2022 Jan 27;8:785744.
3: Liu S, Liu S, Wang Y, Liao Z. The P2/P2′ sites affect the substrate cleavage of TNF-α converting enzyme (TACE) Mol Immunol. 2014 Nov;62(1):122-8.
4: Sato K, Takaishi M, Tokuoka S, Sano S. Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model PLoS One. 2014 Nov 10;9(11):e112408.
5: Black RA, Doedens JR, Mahimkar R, Johnson R, Guo L, Wallace A, Virca D, Eisenman J, Slack J, Castner B, Sunnarborg SW, Lee DC, Cowling R, Jin G, Charrier K, Peschon JJ, Paxton R. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity Biochem Soc Symp. 2003;(70):39-52.
6: Lambert MH, Blackburn RK, Seaton TD, Kassel DB, Kinder DS, Leesnitzer MA, Bickett DM, Warner JR, Andersen MW, Badiang JG, Cowan DJ, Gaul MD, Petrov KG, Rabinowitz MH, Wiethe RW, Becherer JD, McDougald DL, Musso DL, Andrews RC, Moss ML. Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping Comb Chem High Throughput Screen. 2005 Jun;8(4):327-39.
7: Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W, Moyer M, Patel I, Waitt GM, Becherer JD, Moss ML, Milla ME. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity Biochemistry. 2002 Jul 30;41(30):9462-9.
8: Rego SL, Helms RS, Dréau D. Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer Immunol Res. 2014 Jan;58(1):87-100.
9: Serwin AB, Sokolowska M, Dylejko E, Chodynicka B. Tumour necrosis factor (TNF-alpha) alpha converting enzyme and soluble TNF-alpha receptor type 1 in psoriasis patients in relation to the chronic alcohol consumption J Eur Acad Dermatol Venereol. 2008 Jun;22(6):712-7.
10: Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knäuper V, Docherty AJ, Murphy G. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3 FEBS Lett. 1998 Sep 11;435(1):39-44.

Products Related to TNF Coverting Enzyme Substrate can be found at Substrates